U.S. Appln. No. 09/523,033 Atty. Docket: TCS-428.0 US-1

## **AMENDMENTS TO THE CLAIMS**

## (deletions shown by strikethrough; additions underlined)

## What is claimed is:

8.

(CURRENTLY AMENDED)

(CURRENTLY AMENDED) A method of inducing an immune response that increases HDL
cholesterol levels in a mammal exhibiting or at risk of exhibiting low levels of serum HDL
cholesterol comprising administering to said mammal an immunogenic composition comprising a
full-length cholesteryl ester transfer protein (CETP) and further comprising a carrier linked to
said protein and wherein said immunogenic composition is capable of raising antibodies that
recognize said mammal's endogenous CETP.

- (canceled)
   (canceled)
   (canceled)
   (canceled)
   (canceled)
   (canceled)
   (curceled)
   (CURRENTLY AMENDED) The method of Claim [[6]]\_1, wherein said carrier is selected from the group consisting of keyhole limpet hemocyanin (KLH), ovalbumin, and Diptheria toxoid.
- 9. (PREVIOUSLY PRESENTED) The method of Claim 1, wherein said administration is repeated.

wherein said composition is administered with an adjuvant.

The method of any one of claims 1, 2, 5, 6, and Claim 1 or 7,

10. (CURRENLTY AMENDED) The method of Claim [[6]] 1, wherein said full-length CETP is the native CETP of said mammal.

U.S. Appln. No. 09/523,033 Atty. Docket: TCS-428.0 US-1

11. (CURRENTLY AMENDED) The method of Claim 1 or 6, wherein said full-length CETP is a human CETP.

- 12. (CURRENTLY AMENDED) The method of Claim 1 or 6, wherein said full-length CETP is a rabbit CETP.
- 13. (CURRENTLY AMENDED) The method of Claim 1 or 6, wherein said full-length CETP differs from the native CETP of said mammal.